Bromazolam
Designer triazolobenzodiazepine (8-bromo analog of alprazolam) sold in the illicit supply, typically as pressed "pills" or powder, often adulterating street opioids. Similar binding profile to alprazolam with comparable anxiolytic, hypnotic, and amnestic effects. Plasma half-life estimated ~17-18 h in limited published cases. No medical indication; scheduled or controlled in most jurisdictions. Overdose risk is amplified by co-use with opioids and ethanol.
Projected serum levels — 1 mg, as needed (shown daily)
Maintenance schedule: 1 mg as needed (shown daily) (oral).
Loading schedule: 2.7 mg on day 1, then 1 mg as needed (shown daily) — reaching therapeutic levels sooner.
Modeled steady state after ~4 days: peak ≈ 2.1 mg, trough ≈ 1.4 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Benzodiazepine
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 36 h
- Common dose
- 1 mg
- Reference dose range
- 0.50–2 mg (single dose)
- Suggested cadence
- as needed (shown daily)
Documented interactions
-
watch
GABA (Gamma-Aminobutyric Acid) + Bromazolam
Bromazolam and GABA (Gamma-Aminobutyric Acid) both push the gaba a in the same direction.
-
watch
Ivermectin (Stromectol) + Bromazolam
Bromazolam and Ivermectin (Stromectol) both push the gaba a in the same direction.
-
watch
L-Theanine + Bromazolam
Bromazolam and L-Theanine both push the gaba a in the same direction.
-
watch
Taurine + Bromazolam
Bromazolam and Taurine both push the gaba a in the same direction.
Serum checks 4 modeled interaction pairings for bromazolam across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Bromazolam blood concentrations in postmortem cases — a British Columbia, Canada experience
Forensic case series documenting bromazolam in postmortem blood (median ~70 ng/mL); most cases involved polydrug intoxication with fentanyl and other opioids, underscoring the drug's role in the opioid-adulteration…
-
Characterization of the designer benzodiazepine bromazolam
In vitro receptor binding and metabolic characterization of bromazolam showing high-affinity GABA-A benzodiazepine-site binding and CYP3A4-mediated hydroxylation consistent with alprazolam class behavior.
2 published studies referenced in the app, each with a plain-language summary.